fda banned semaglutide US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list FDA moves to remove GLP-1

In the SUSTAIN clinical trial program evaluating injectable semaglutide for type 2 diabetes, the 1 mg weekly dose reduced HbA1c by approximately 1.41.6% from baseline, while the SUSTAIN FORTE trial showed that the 2 mg dose provided additional glycemic benefits for patients needing intensification

By integrating evidence-based treatments like GLP-1 medications into your wellness journey, we can work together to address core health concerns, improve your cholesterol, and promote your heart health in a comprehensive and sustainable way.

Therefore, while Ozempic does not directly alter potassium, the clinical picture requires careful consideration of the patient's overall medication regimen and symptom profile

Ozempic is a medication for chronic weight management, not a cosmetic solution